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Summary
Background Comparative, real-life and long-term evidence on the effectiveness and safety
of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is lim-
ited. Such data must come from well-designed prospective patient registries. Standard-
ization of data collection is needed for direct comparisons and data pooling.
Objectives To reach a consensus on how and when to measure the previously defined
domain items of the TREatment of ATopic eczema (TREAT) Registry Taskforce core
dataset for research registries for paediatric and adult patients with AE.
Methods Proposals for the measurement instruments were based on recommenda-
tions of the Harmonising Outcome Measures for Eczema (HOME) initiative, the
existing AE database of TREATgermany, systematic reviews of the literature and
expert opinions. The proposals were discussed at three face-to-face consensus
meetings, one teleconference and via e-mail. The frequency of follow-up visits
was determined by an expert survey.
Results A total of 16 experts from seven countries participated in the ‘how to
measure’ consensus process and 12 external experts were consulted. A consensus
was reached for all domain items on how they should be measured by assigning
measurement instruments. A minimum follow-up frequency of initially 4 weeks
after commencing treatment, then every 3 months while on treatment and every
6 months while off treatment was defined.
Conclusions This core dataset for national AE research registries will aid in the
comparability and pooling of data across centres and country borders, and
enables international collaboration to assess the long-term effectiveness and safety
of phototherapy and systemic therapy used in patients with AE.
© 2019 The Authors. British Journal of Dermatology
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What’s already known about this topic?
• Comparable, real-life and long-term data on the effectiveness and safety of pho-
totherapy and systemic therapy in patients with atopic eczema (AE) are needed.
• There is a high diversity of outcomes and instruments used in AE research, which
require harmonization to enhance comparability and allow data pooling.
What does this study add?
• Our taskforce has reached international consensus on how and when to measure
core domain items for national AE research registries.
• This core dataset is now available for use by researchers worldwide and will aid in
the collection of unified data.
What are the clinical implications of this work?
• The data collected through this core dataset will help to gain better insights into
the long-term effectiveness and safety of phototherapy and systemic therapy in AE
and will provide important information for clinical practice.
• Standardization of such data collection at the national level will also allow direct
data comparisons and pooling across country borders (e.g. in the analysis of treat-
ment-related adverse events that require large patient numbers).
A significant number of paediatric and adult patients with
moderate-to-severe atopic eczema (AE) may require pho-
totherapy or systemic immunomodulatory therapy at some
point during their life. For adults, ciclosporin, and recently
dupilumab, are currently the only systemic therapies that are
approved by the European Medicines Agency,1,2 while only
dupilumab has been approved by the U.S. Food and Drug
Administration.3 For children, there are no approved systemic
therapies, although our European and North American treat-
ment surveys show that they are regularly prescribed.4,5 While
there is some evidence on the short-term effectiveness of pho-
totherapy and systemic immunomodulatory therapy, there is a
clear lack of head-to-head comparison trials and a paucity of
data on the long-term effectiveness and safety of such treat-
ments.6,7 As randomized controlled trials have very strict
inclusion criteria, important subgroups of patients (e.g. those
with comorbidities) are commonly excluded and therefore
evidence in real-life populations is missing. All of this requires
data collection from well-defined patient cohorts.8–10
To harmonize data collection for such observational cohorts,
the TREatment of ATopic eczema (TREAT) Registry Taskforce
initiated a consensus exercise to develop a core set of domains
and domain items for AE treatment research registries. After
an international Delphi study and consensus meeting, the core
dataset (‘what to measure’) was agreed on, consisting of 19
domains with 69 corresponding domain items (49 at baseline
and 20 at follow-up).11,12
As the next step in this consensus-finding process, we per-
formed a consensus exercise to define how and when to
measure the core domain items to harmonize data collection
fully within national AE treatment research registries and pre-
vent heterogeneity.13,14
Patients and methods
Study design
To establish a core set of measurement instruments (‘how to
measure’), three face-to-face expert consensus meetings, one
teleconference and final discussions via e-mail were arranged.
For this process we used the following sources to guide deci-
sion making: (i) recommendations from the Harmonising
Outcome Measures for Eczema (HOME) initiative were used
where possible (e.g. regarding the capture of clinical signs,
patient-reported outcomes and quality of life);15–17 (ii) rele-
vant literature, in particular systematic reviews considering
measurement instruments in AE;7,13,14,18–20 (iii) the existing
AE database of TREATgermany,21 which already included over
100 patients at the start of this study; (iv) personal communi-
cations with experts in the field of measurement instruments
for specific domain items [e.g. K. McElhone (British Associa-
tion of Dermatologists Biologics and Immunomodulators
Register; BADBIR), personal communication]; and (v) the cur-
rent use of measurement instruments in clinical practice and
clinical expertise of the participants. During all meetings, fea-
sibility and current common practice were kept in mind.
All meetings were chaired by either P.I.S. or C.F. During
each session, the evidence for each suggested measurement
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 181, pp492–504
Consensus on measurement of core dataset for AE treatment research registries, F.M. Vermeulen et al. 493
instrument was presented in the form of a PowerPoint presen-
tation and written handouts, followed by whole group discus-
sions. These discussions were iterative and continued until full
consensus was achieved. Voting was done by a show of hands
and was therefore not anonymous. Whenever possible, vali-
dated measurement instruments were selected. If multiple vali-
dated instruments were available, decisions were based on (in
order of importance): (i) HOME recommendations; (ii) qual-
ity of the validation studies; and (iii) the feasibility and, in
particular, the potential to be used in different countries, and
the number of available translations of the measurement
instrument. In case the consensus on domain items could not
be reached immediately during the meetings (e.g. due to a
lack of evidence), items were assigned to participating TREAT
members for further investigation, taking into account their
areas of expertise. These items were then rediscussed at the
next consensus meeting. The three face-to-face consensus
meetings were audiorecorded for reference at the next
meetings.
To define when the domain items should be measured
(‘when to measure’), in September 2017 we conducted an
online survey among all participants using SurveyMonkey soft-
ware. Options put to the vote were based on current clinical
practice (Fig. S1; see Supporting Information). The results of
the survey were discussed and approved in a small group via
e-mail.
Participants
The participants were physicians, patients and nonclinical
researchers (i.e. health economists, epidemiologists/method-
ologists) from the TREAT Registry Taskforce with an interest
in AE and/or AE measurement instruments. We also consulted
external experts through personal communications (mostly
e-mail) from, for example, the Coronel Institute of Occupa-
tional Health and the Medical Psychology Department of the
Academic Medical Centre in Amsterdam for items considering
work and health, and items considering treatment adherence.
Definition of consensus
Consensus was predefined both for the ‘how to measure’ and
for the ‘when to measure’. Consensus for the ‘how to mea-
sure’ was achieved when 100% of the participants present
during the consensus meeting agreed on the measurement
instrument. Consensus on the follow-up frequency and the
visit window (‘when to measure’) was achieved when the
majority of the participants voted for one of the options.
Results
How to measure
In March, May and June 2017 four consensus meetings were
held. The first was done by teleconference and the other three
were by face-to-face meetings in London, Amsterdam and
Nantes. A total of 16 participants met, all members of the
TREAT Registry Taskforce, including 11 academic dermatolo-
gists, one dermatology resident, one dermatology PhD stu-
dent, one patient/patient representative, one epidemiologist/
methodologist, and one health economist (Fig. S2; see Sup-
porting Information). A total of 12 experts were consulted for
specific items.
During the face-to-face meetings, slight alterations were
made to the ‘what to measure’ core dataset. To make the core
dataset as feasible as possible some domain items were merged
with others. The items ‘medical history’, ‘follow-up (FU)
safety bloods’, ‘adverse events that cause stop or switch of
therapy or change in dosage’ and ‘probability of relationship
with treatment’ are now captured as part of the other items
(for details see Table 1). Additionally, the items ‘other signifi-
cant illnesses’ and ‘other medication relevant for AE treatment
response’ were added as they were not previously captured in
the ‘what to measure’ core dataset. After these alterations, the
final ‘what to measure’ core dataset consists of 70 items (50
baseline items and 20 follow-up items; Table 1). For all items,
consensus was reached on the measurement instruments.
Details on specific domain items
Ethnicity
We reviewed all ethnicity classifications that we had access to,
based on a literature search, including the one used by the U.K.
Biobank, the German National Cohort and BADBIR. The classifi-
cation system shown in Table 1 was made (based on all these
reviewed classification systems) and was selected because this
system allows patients and physicians to choose from an exten-
sive list of ethnicities. The option to select and specify two eth-
nicities is given as well. To capture migration, country of birth
of patient and parents were also added.
Educational status
Educational status is an important predictor of health and dis-
ease.22 For this item, the International Standard Classification
of Education (ISCED) system was chosen. The ISCED has, for
instance, been adopted by the United Nations Educational, Sci-
entific and Cultural Organization General Conference and con-
sists of definitions that have been agreed on internationally.
Further, it facilitates the comparison of education systems
from different countries. The group agreed that each country
would translate this classification to its national educational
classification.
It was decided to record the highest completed educational
level (from the parent or child in case of a child or from the
patient themselves if an adult).
Use of validated diagnostic criteria
Both the quality of the gathered data and the feasibility of the
registry were considered. Many lists of diagnostic criteria for
© 2019 The Authors. British Journal of Dermatology
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Table 1 Core dataset of domains, domain items and measurement instruments to be captured in national atopic eczema treatment registries
Domains Domain items How to measure Comments
Demographics Date of birth
Date of enrolment into
registry
1. Date
2. Date
Gender 1. Male, female, other
Ethnicity 1. Country of birth of patient and parents
2. Ethnicity of patient (possibility to select
two options): White (Europe, Russia, Middle
East, North Africa, U.S.A., Canada,
Australia), Black-African, Afro Caribbean,
African American, Asian-Chinese, South
Asian (India, Pakistan, Sri Lanka, Nepal,
Bhutan, Bangladesh), Asian—other (Korea,
China north of Huai River), Japanese,
Hispanic or Latino, mixed—please specify,
other—please specify
Educational status 1. ISCED classification (for both adults and
children):
ISCED 0: Early childhood education
ISCED 1: Primary education
ISCED 2: Lower secondary education
ISCED 3: Upper secondary education
ISCED 4: Post-secondary non-tertiary
education
ISCED 5: Short-cycle tertiary education
ISCED 6: Bachelor’s or equivalent level
ISCED 7: Master’s or equivalent level
ISCED 8: Doctoral or equivalent level
This item will be assessed repeatedly
Use the highest completed education
level; from child or parents if a child
or from the patient themselves if adult
Will have to be translated for each
country to its national educational
classification
Current occupation or
education
1. Eurostat classifications 1–8: 1. employed,
2. self-employed, 3. disability pension
(unable to work), 4. retired, 5. student or
pupil, 6. engaged on home duties, 7.
unemployed, 8. other—please specify
This item will be assessed repeatedly
AE diagnosis How diagnosis AE is
established
1. Clinically Y/N
2. Histopathology Y/N
Use of validated
diagnostic criteria
1. Physician diagnosis alone, Hanifin & Rajka
Criteria, U.K. Working Party Diagnostic
Criteria, AAD/Eichenfield Criteria, Refined
Millennium Criteria, Schultz-Larsen Criteria,
Kang and Tian Criteria, Diepgen Criteria,
Danish Allergen Research Centre Criteria,
Saeki’s JDA Criteria
Each country can decide which of these
criteria they want to give as options
Date of onset AE 1. Year
Past AE treatments Phototherapy 1. Y/N
2. NB-UVB, BB-UVB, UVB (unspecified),
UVA, UVA1, UVAB, PUVA (oral or other),
other (possibility to select multiple options)
3. How many courses (numerical),
cumulative dose (J/cm2) (optional), when
(start year) (optional), number of treatments
within a course (numerical) (optional),
outcome: a. effect (excellent (clearance),
good, moderate, poor), b. reason to stop
(insufficient response, loss of treatment
response (after initial good response),
side-effects, cumulative dose, disease
remission, other) (select one option),
c. adverse event (Y/N)
UVB (unspecified) if type is unknown
This is only medical history. If (also)
current it should be recorded under
‘current AE treatments’
(continued)
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Table 1 (continued)
Domains Domain items How to measure Comments
Systemic therapy 1. Y/N
2. Ciclosporin, azathioprine, methotrexate,
mycophenolate acid, systemic
corticosteroids, dupilumab, omalizumab,
other—please specify, investigational
medication—please specify (possibility to
select multiple options)
3. How many courses (numerical), when (start
month + year) (optional), duration (free text),
average treatment (maintenance) dose
(optional), outcome: a. effect (excellent
(clearance), good, moderate, poor), b. reason
to stop (insufficient response, loss of treatment
response (after initial good response),
side-effects, cumulative dose, disease
remission, other), c. adverse event (Y/N)
With definitions for average treatment
(maintenance) dose (Fig. S4; see
Supporting Information)
This is only medical history. If (also)
current it should be recorded under
‘current AE treatments’
Topical treatments for AE 1. Y/N
2. Corticosteroids, calcineurin inhibitors, tar
ointments, crisaborole, other (possibility to
select multiple options)
Only to be registered for the past year
This is only medical history. If (also)
current it should be recorded under
‘current AE treatments’
Day hospital care
treatments for AE
(outpatient)
1. Y/N
2. Duration (cumulative treatment days)
Only to be registered for the past year
This is only medical history. If (also)
current it should be recorded under
‘current AE treatments’
Hospitalization for AE 1. Y/N
2. Duration (cumulative days)
Only to be registered for the past year
This is only medical history. If (also)
current it should be recorded under
‘current AE treatments’
Current AE treatments Phototherapy 1. Y/N
2. NB-UVB, BB-UVB, UVA, UVA1, UVAB,
PUVA (oral or other), other
3. Start date, cumulative dose (J/cm2), stop
date
Systemic therapy 1. Y/N
2. Ciclosporin, azathioprine, methotrexate,
mycophenolate acid, systemic
corticosteroids, dupilumab, omalizumab,
other—please specify, investigational
medication—please specify (possibility to
select multiple options)
3. Start date, start dose, current dose, stop
date
With definitions for average treatment
(maintenance) dose (Fig. S4; see
Supporting Information)
Topical treatments 1. Y/N
2. Corticosteroids, calcineurin inhibitors, tar
ointments, crisaborole, other (possibility to
select multiple options)
3. Classification of steroids and calcineurin
inhibitors (optional)
4. Frequency (‘how many times a week do
you use it?’) (optional)
If classification is registered use the
national official potency classification
Amount of topical
creams/ointments used
per week (g)
1. <30, 30–60, 60–100, >100 This is exclusive additive-free, bland
emollients
Family history of AE
or allergic diseases
Family history of AE or
allergic diseases
1. Y/N
2. Atopic eczema, asthma, allergic
rhinoconjunctivitis, atopic eye disease,
eosinophilic oesophagitis, other (possibility
to select multiple options)
Y if first-degree relative (parents or
children)
According to the patient or physician-
diagnosed
(continued)
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Table 1 (continued)
Domains Domain items How to measure Comments
Allergic comorbidities Asthma 1. Physician diagnosed Y/N
Allergic
rhinoconjunctivitis
1. Physician diagnosed Y/N
Atopic eye disease 1. Physician diagnosed Y/N
Eosinophilic oesophagitis 1. Physician diagnosed Y/N
Food allergies 1. Do you have a food allergy currently? Y/N
2. If yes, is at least one food allergy
diagnosed by a doctor? Y/N
3. If yes, how was this diagnosis made?
Double-blind placebo-controlled oral food
challenge, open food challenge, skin prick
tests, scratch tests, positive food allergen-
specific IgE test, other (e.g. atopy patch
test), unknown
Contact allergies 1. Have you ever been tested for contact
allergies with patch tests? Y/N, unknown
2. If yes, what was the outcome? Positive,
negative, unknown
Other past and
current
comorbidities
Malignancies 1. Y/N
2. When (year)
3. Type of malignancy (free text)
4. Active, remission, relapsed
MedDRA categories will be used for this
item as much as possible
Serious infections 1. Y/N
2. When (year)
3. Type of infection (free text)
4. Active, latent, resolved (cured)
MedDRA categories will be used for this
item as much as possible
Includes ‘medical history’ (tuberculosis,
HIV, hepatitis B or C); original item of
domain baseline assessments
Other significant illnesses 1. Y/N
2. When (year)
3. Type of illness (free text)
4. Active, remission, resolved (cured),
relapsed
MedDRA categories will be used for this
item as much as possible
Current concomitant
medication (i.e.
other than specific
AE medication)
Antihistamines 1. Y/N
2. Oral, topical
Antibiotics 1. Y/N
2. Oral, topical
Other medication relevant
for AE treatment
response
1. Y/N
2. Which (free text)
Includes
‘immunotherapy’
Relevant according to judgement of
treating physician
Immunosuppressives for
other inflammatory
diseases
1. Y/N
2. Which (free text)
3. Indication: inflammatory bowel disease,
rheumatoid arthritis, other—please specify
4. Start date, stop date
5. Current dose (free text)
Baseline general AE
questions
Exposures that trigger
disease flares
1. Y/N
2. Stress, infection, weather conditions,
sweating/exercise, exposure to aero-
allergens, other (possibility to select multiple
options)
Episodes of skin infection 1. Y/N
2. Bacterial skin infection (folliculitis,
impetigo, etc.), viral skin infection (HSV
infection, molluscum contagiosum, etc.)
(possibility to select multiple options)
(continued)
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Table 1 (continued)
Domains Domain items How to measure Comments
Days lost from usual
activities (e.g. work,
study)
1. Y/N
2. Days per month (free text)
Average number of days in the past 3
months
Baseline physical
examination
Fitzpatrick skin type 1. I, II, III, IV, V, VI
Skin examination 1. Flexural eczema: select involved areas
(individual patches have to be ≥ 1 cm): skin
folds around the eye(s), neck (front),
flexures of the arm(s), flexures of the leg(s),
front of ankle(s), not applicable
2. Non-flexural eczema: select involved areas
(individual patches have to be ≥ 2 cm and,
excluding the face, on both sides): face,
extensor of elbows, arms, extensor of knees,
legs, hands, not applicable
3. Presence of (Y/N): (history of)
pompholyx, discoid eczema, nodular
prurigo, follicular eczema, ichthyosis,
keratosis pilaris, palmar hyperlinearity,
erythroderma, skin infection (if Y: bacterial/
viral/fungal, sample taken Y/N)
For definitions on these phenotypical
and morphological characteristics see
Figure S3 (see Supporting Information)
Baseline physician-
and patient-reported
domains
Physician-assessed clinical
signs
1. EASI
2. SCORAD (optional)
Objective or full SCORAD. If the full
SCORAD is used, the objective and
subjective SCORAD need to be reported
separately
Investigator/physician
global assessment
1. vIGA-ADTM scale (five-point)
Patient-reported
symptoms
1. POEM
2. Peak pruritus NRS (0–10) past 24 h
3. Peak VAS pain (0–10) past 24 h (optional)
Patient global assessment 1. Patient Global Assessment five-point
Generic quality of life
score
1. EQ-5D (version 5L and Y) Adults EQ-5D-5L;
children EQ-5D-Y; caregivers (proxies)
EQ-5D-Y and EQ-5D-5L
Awaiting the index score for the
EQ-5D-Y
Skin-specific quality of
life score
1. DLQI, CDLQI, IDQoL DLQI > 16 years; CDLQI 4–16 years;
IDQoL < 4 years
Patient-reported
satisfaction with AE care
received
1. How satisfied are you with the care
received for your AE since the last visit?
(five-point Likert scale)
2. How satisfied are you with the treatment
received for your AE since the last visit?
(five-point Likert scale)
The wording may change in the future
if a validated measurement tool
becomes available
Satisfaction with care is broad and
includes for instance satisfaction with
treatment, physician and the hospital
Impact of AE on the
family
1. FDLQI Needs to be filled out within the visit
window (according to the patients
visit) by adult family members or the
partner of the patient
Preferably the FDLQI is answered by the
same person every time
Baseline investigations Full blood count 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Normal/abnormal according to local
standards
Liver function 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Normal/abnormal according to local
standards
(continued)
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Table 1 (continued)
Domains Domain items How to measure Comments
Kidney profile 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Normal/abnormal according to local
standards
Evaluating TPMT level
before azathioprine use
1. Y/N, not applicable
2. Low or absent, intermediate, normal or
high
Baseline management Main reasons for
choosing specific
treatment (systemic or
phototherapy)
1. Existent comorbidities and/or results of
baseline investigations including abnormal
laboratory results, patient age, anticipation of
pregnancy and other family planning issues
for both males and females, history of prior
systemic therapies (incl. response), drug
safety and side-effect profile, therapeutic
profile: a. speed of onset, b. magnitude of
effect, c. better long-term control after drug
is stopped, accessibility of the treatment
(including licensing), patient preferences,
other (possibility to select 3 options)
Relative contraindication
(s) for selected
treatment
1. Y/N
2. Which (free text)
Follow-up general AE
questions
Days lost from usual
activities
1. Y/N
2. Days per month (free text)
Average number of days since the last
visit
Change in diagnosis after
enrolment
1. Y/N
2. CTCL, other
Date of death and relation
to AE
1. Date, not applicable
2. Not related, doubtful, possible, probable,
very likely, definite
Follow-up physical
examination
Skin examination 1. Flexural eczema: select involved areas
(individual patches have to be ≥ 1 cm): skin
folds around the eye(s), neck (front),
flexures of the arm(s), flexures of the leg(s),
front of ankle(s), not applicable
2. Non-flexural eczema: select involved areas
(individual patches have to be ≥ 2 cm and,
excluding the face, on both sides): face,
extensor of elbows, arms, extensor of knees,
legs, hands, not applicable
3. Presence of (Y/N): (history of)
pompholyx, discoid eczema, nodular
prurigo, follicular eczema, ichthyosis,
keratosis pilaris, palmar hyperlinearity,
erythroderma, skin infection (if Y: bacterial/
viral/fungal, sample taken Y/N)
Same comment(s) as for baseline item
Follow-up physician-
and patient-reported
domains
Physician-assessed clinical
signs
1. EASI
2. SCORAD (optional)
Same comment(s) as for baseline item
Investigator/physician
global assessment
1. vIGA-ADTM scale (five-point)
Patient-reported
symptoms
1. POEM
2. Peak pruritus NRS scale (0–10) past 24 h
3. Peak VAS pain (0–10) past 24 h (optional)
Patient global assessment 1. Patient Global Assessment five-point
Generic quality of life
score
1. EQ-5D (version 5L and Y) Same comment(s) as for baseline item
Skin-specific quality of
life score
1. DLQI, CDLQI, IDQoL Same comment(s) as for baseline item
(continued)
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Table 1 (continued)
Domains Domain items How to measure Comments
Reporting of disease
control
– HOME results showed that for now this
should be registered by repeated
measurements of clinical signs,
symptoms, quality of life and a patient
global instrument (a specific
instrument is not yet defined by
HOME)
Adherence to treatment
between appointments
1. MARS (optional) To be adjusted for AE, until then
optional
Patient-reported
satisfaction with AE care
received
1. How satisfied are you with the care
received for your AE since the last visit?
(five-point Likert scale)
2. How satisfied are you with the treatment
received for your AE since the last visit?
(five-point Likert scale)
3. PsoSaT (optional)
PsoSat to be adjusted for AE
Further comment(s) same as for baseline
item
Impact of AE on the
family
1. FDLQI Same comment(s) as for baseline item
Follow-up
investigations
Full blood count 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Previously captured as ‘safety bloods’
Further comment(s) same as for baseline
item
Liver function 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Previously captured as ‘safety bloods’
Further comment(s) same as for baseline
item
Kidney profile 1. Y/N
2. Normal, abnormal
3. Clinically relevant Y/N
Previously captured as ‘safety bloods’
Further comment(s) same as for baseline
item
Follow-up adverse
events
Severe adverse events 1. Y/N
2. Diagnosis (free text)
3. In case of a serious adverse event: death,
life-threatening, hospitalization or prolonged
hospitalization of existing hospitalization,
persistent or significant disability, congenital
anomaly, important medical event that
requires medical intervention, not applicable
(possibility to select multiple options)
4. Relatedness: not related, doubtful, possible,
probable, very likely, definite
5. Action: Stop, switch of therapy, change in
dosage, not applicable
MedDRA categories will be used for this
item as much as possible
Severe according to judgement of
treating physician
Follow-up
management
Reason for switching
therapy
1. Efficacy, inefficacy, adverse event(s),
interaction with other medication, child
wish, patient request, other, not applicable
(possibility to select multiple options)
Reason for
discontinuation of
therapy
1. Efficacy, inefficacy, adverse event(s),
interaction with other medication, child
wish, patient request, other, not applicable
(possibility to select multiple options)
AAD, American Academy of Dermatology; AE, atopic eczema; BB-UVB, broadband ultraviolet B; CDLQI, Children’s Dermatology Life Quality
Index; CTCL, cutaneous T cell lymphoma; DLQI, Dermatology Quality of Life Index; EASI, Eczema Area and Severity Index; EQ-5D, EuroQol
five-Dimensional; FDLQI, Family Dermatology Life Quality Index; HSV, herpes simplex virus; HOME, Harmonising Outcome Measures for
Eczema; IDQoL, Infant’s Dermatitis Quality of Life Index; ISCED, International Standard Classification of Education; JDA, Japanese Dermato-
logical Association; MARS, Medication Adherence Report Scale; MedDRA, Medical Dictionary for Regulatory Activities; N, no; NB-UVB, nar-
rowband ultraviolet B; NRS, numerical rating scale; POEM, Patient Oriented Eczema Measure; PsoSat, Psoriasis Satisfaction questionnaire;
PUVA, psoralen and ultraviolet A; QoLIAD, Quality of Life Index for Atopic Dermatitis; SCORAD, SCORing Atopic Dermatitis; TPMT, thiop-
urine methyltransferase; UVA, ultraviolet A; UVAB, ultraviolet A plus ultraviolet B; UVB, ultraviolet B; VAS, visual analogue scale; vIGA-AD,
Validated Investigator Global Assessment scale for Atopic Dermatitis; Y, yes.
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AE are available and reviewed (e.g. the U.K. Working Party
criteria, Hanifin and Rajka criteria, refined Millennium Crite-
ria).23 Although in clinical practice a diagnosis of AE is often
made without the use of specific diagnostic criteria, neverthe-
less the use of validated diagnostic criteria is desirable within
the context of national AE treatment research registries. During
the consensus exercise, we decided to give national registries
the option to decide which validated diagnostic criteria they
would like to use. In addition, the option ‘physician diag-
nosed’ was added in case no diagnostic criteria were used.
Previous and current phototherapy and systemic therapy
In addition to recording the type, dose and outcome of past
therapies, we also recommend to capture the number of treat-
ment courses, the average treatment (maintenance) dose and
whether adverse events associated with these treatments
occurred. Where available, we also recommend recording the
cumulative dose of phototherapy. It was decided to add inves-
tigational therapies to the registry (both for past and current
systemic therapies), although during the initial Delphi exer-
cise, this was voted out.
Current topical treatments
The question was whether or not to register the potency of
corticosteroids as the classification differs between countries.
For feasibility reasons it was therefore decided to recommend
registration of the potency using the known national classifica-
tion system, but this is not mandatory.
Malignancies, serious infections and other significant
illnesses
While only past malignancies and past serious infections were
voted in during the Delphi exercise, the knowledge of current
malignancies, infections and other comorbidities provide us
with important information for safety and subgroup analyses.
Thus, these items were added. The item ‘medical history’ (tu-
berculosis, HIV, hepatitis B or C), which was previously voted
in during the Delphi exercise, is now captured as part of the
item ‘past serious infections’.
Other medication relevant for an atopic eczema treatment
response
Although not voted in during the ‘what to measure’ Delphi
process, this item has been added, as such therapies (e.g.
immunotherapy or aeroallergens) might need to be considered
as a confounder of the response to AE treatments.
Days lost from usual activities
Some of the costs of AE are associated with decreased produc-
tivity or days lost from work.24 Registration of the days lost
from work is important to register for health technology
assessment and cost-effectiveness research. However, this
would bias results towards those patients in productive areas.
Hence, the name of this item was changed to ‘days lost from
usual activities’.
Skin examination
Treatment response might be influenced by the phenotype of
AE. Therefore, we suggest to document whether certain phe-
notypical and morphological characteristics are present. For
definitions on these characteristics see Figure S3 (see Support-
ing Information).
Details on the physician- and patient-reported domain
items
Physician-assessed clinical signs and patient-reported
symptoms
For all items, HOME recommendations were followed, that is,
the Eczema Area and Severity Index was selected for the item
‘physician-assessed clinical signs’15 and the Patient-Oriented
Eczema Measure (POEM) was selected for the item ‘patient-
reported symptoms’.16,25,26
Patient-reported symptoms
At the fifth meeting of HOME (HOME V) it was agreed that
the inclusion of intensity of itch should be investigated, as the
POEM only measures frequency of itch.17 Schoch et al. and
Phan et al. found that the 11-point numerical rating scale
(NRS) for itch has good reliability and validity and that recall
bias increases with the recall period.18,27 The 11-point (NRS)
was therefore added to the item ‘patient-reported symptoms’
and after consultation with external experts it was decided to
register the peak itch for the previous 24 h.28
Reporting of disease control
For this item, which is analogous to the long-term control
domain as defined by HOME, HOME V has recommended the
use of repeated measurements of the long-term control sub-
domains: clinical signs, symptoms, quality of life and a patient
global instrument.17
Investigator/Physician Global Assessment
Futamura et al. concluded that global assessments are often used
in AE research but comparisons are hard because there are no
standardized definitions.29 Therefore, the International Eczema
Council and Eli Lilly and Company have worked on a validated
five-point Investigator Global Assessment (IGA) scale, which
was incorporated in to the core dataset for this item.30,31
Patient global assessment
Little research has been done towards the patient global assess-
ment (PGA). This subdomain of the long-term control domain
has been discussed during HOME V, but as yet stays unde-
fined.17 However, as we decided to use the five-point IGA
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scale, the five-point PGA for the item ‘patient global assess-
ment’ was chosen.
Skin-specific quality-of-life score
For this item, during the HOME IV (adults) and HOME V (chil-
dren) meetings it was concluded that there is currently no mea-
surement instrument that can be recommended.16,17,19,20
Considering feasibility and the most commonly used instru-
ments, it was decided to use the Dermatology Life Quality Index
(DLQI), the Children’s DLQI (CDLQI) and the Infants’ Dermati-
tis Quality of Life Index (IDQoL). Further validation work on the
DLQI was recently published by Patel et al.32
Generic quality-of-life score
Feasibility, access to different languages and the high degree
of usage were the main reasons to choose the EQ-5D-5L
(adults) and the EQ-5D-Y (children) as the preferred measure-
ment instruments for this item.
Patient-reported satisfaction with atopic eczema care
received, impact of atopic eczema on the family and
adherence to treatment between appointments
We recommend the use of an adapted Psoriasis Satisfaction
questionnaire (PsoSat), a questionnaire that measures the treat-
ment satisfaction in patients with psoriasis,33 the Family Der-
matology Life Quality Index34 and the Medication Adherence
Report Scale (MARS), which was originally developed for the
adherence with oral medication in asthma but can be easily
adapted for patients with AE.35 The MARS will be optional
until it is validated for AE.
When to measure
Thirteen of 16 participants (81%) completed the survey. Eight
of 13 (62%) voted for a minimum follow-up frequency of every
3 months while on therapy; seven of 13 participants (54%)
voted for an extra visit 4 weeks after baseline. Seven of 13 partic-
ipants (54%) voted for a minimum follow-up frequency of
every 6 months while off treatment. The recommended visit
window for patients both on and off therapy was set at +/ 1
month (58% and 50%). An overview is shown in Table 2.
Discussion
This consensus study identified measurement instruments for
all domain items previously agreed on during our Delphi
study for AE research registries that capture data on adults and
children with moderate-to-severe AE on phototherapy and sys-
temic immunomodulatory therapy. By doing so, a complete
core dataset is now available for usage by researchers world-
wide.
Our recommendations for core domains and domain items
for data collection were based on a carefully conducted inter-
national Delphi process, in which over 400 stakeholders
(physicians, nurses, patients, methodologists, regulatory body
and industry representatives) from over 30 countries con-
tributed.11,12 The results of this Delphi directly fed into the
‘how to measure’ recommendations presented here.12 In addi-
tion, proposals for the measurement instruments were based
on the recommendations from the HOME initiative. Although
primarily meant for clinical trials and not specifically for
research registries, the HOME recommendations represent an
international consensus on core outcomes based on validation
studies and systematic reviews. The experts who participated
in the HOME initiative participated in this study as well,
allowing us to benefit from their expertise. Further, a patient
and experts in the field of AE and/or AE measurement instru-
ments were involved, which strengthened our recommenda-
tions and provided insight into important aspects that will
play a role during implementation of the core dataset.
As for potential limitations, the final decisions on the ‘how
to measure’ were made by a relatively small group for feasibil-
ity reasons, which did not include representatives from the
regulatory bodies or pharmaceutical industry. However, where
required expertise was not available within the group, external
experts were consulted. In addition, because observational
studies need large numbers of patients, this core dataset will
need to be implemented in many research facilities. Although
this might prove to be a challenge, we think that, as many of
the items from the core dataset are already registered in clini-
cal practice, this will not become a problem. Although we
had a very experienced patient representative, who also was
the Chair of the Dutch Association for People with Atopic Der-
matitis, it would have been desirable to include more patient
representatives in this consensus process. Finally, for a number
of domain items no underlying systematic reviews of the evi-
dence were available. This meant that, in this study, expert
opinion played a larger role than, for example, in the HOME
initiative.
As a next step, the feasibility of the core dataset and the
proposed follow-up frequencies need to be tested. As part of
such feasibility work, it is important to keep in mind that our
recommendations apply to research registries, rather than
record keeping in routine clinical practice. We are also
Table 2 When to measure the domain items for national atopic eczema treatment registries
Category When to measure
Follow-up frequency while on therapy 4 weeks, 3 months and then every 3 months
Follow-up frequency while off therapy Every 6 months
Visit window +/1 month
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encouraged that the larger TREATgermany dataset appears fea-
sible to local investigators in its current form.21
This core dataset will allow the international dermatology
community to generate, compare and pool data of patients with
AE on phototherapy and systemic therapy across country borders
to answer important questions on long-term effectiveness, safety
and cost-effectiveness of these therapies; which can only be
addressed with very large patient numbers (e.g. on rare adverse
events). We are working on a standardized data collection/stor-
age platform to facilitate uniform data collection, pooling and
analyses. In the long-term, we hope that our recommendations
and the analyses generated by national treatment registries will
complement the more short-term results from randomized con-
trolled trials and ultimately aid the standardization and optimiza-
tion of patient management.
As the uptake of this core dataset by new national AE reg-
istries is vital, we encourage colleagues to contact us through
our website (https://treat-registry-taskforce.org), to extend
this collaborative project not just within Europe but also
beyond.
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